CHCWM – Cancer & Hematology Centers of West Michigan

CL1-95029-001 ( Servier Pharmaceuticals )

Description:  A Phase 1a/1b, Open-label, Multicenter Trial Investigating the

Safety, Tolerability, and Preliminary Anti-neoplastic Activity of S095029 (Anti-NKG2A) as Monotherapy and in Combination with Sym021 (Anti-PD-1) in Patients with Advanced Solid Tumor Malignancies followed by an Expansion Part with Triplet Combinations of S095029 and Sym021 and an Anti-HER2 mAb or Anti-EGFR mAbs (futuximab/modotuximab) in Patients with Metastatic Gastric or Colorectal Cancers

 Mechanism of Action:  S095029 is an anti NKG2A antibody.  NKG2A is an NK cell immune checkpoint.  SYM21 is a PD1 inhibitor.

 Target Population:  In Monotherapy Dose Escalation.   Patients receive 2 doses of S095029 then receive Sym021 (PD-1 Inhibitor) alone.  Will move to combination and expansion cohorts.

Study Design:  Study drug is administered IV every 2 weeks.